ESMO Press Office

The ESMO Press Office welcomes media professionals interested in reporting on cancer.

For enquiries please contact us on:


ESMO 2017 Updates
ESMO 2017 Press Conference schedule


All ESMO Press Conferences will take place at IFEMA in Hall 10 (Press Area)

The following schedule may be subject to changes

Topic Day Time
Opening Press Conference Friday, 8 Sept 2017 10:45 - 11:30
LBA Press Conference: Lung cancer Saturday, 9 Sept 2017  08:15 - 09:00
Press Conference: Facing the challenges of life after cancer Saturday, 9 Sept 2017  13:45 - 14.30
LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers Sunday, 10 Sept 2017 08:15 - 09:00
LBA Press Conference: Melanoma cancer Monday, 11 Sept 2017  08:15 - 09:00
Press Conference in Spanish Monday, 11 Sept 2017  11:00 - 11:45
Press Conference: How Public policy can affect cancer patient care Monday, 11 Sept 2017  15:00 - 15:45
Wrap-Up press conference Tuesday, 12 Sept 2017  08:15 - 09:00
ESMO 2017 Press Programme


ESMO 2017 Embargo on abstracts

  • Abstracts accepted for presentation at ESMO 2017 as Proffered Paper (oral presentation), Poster Discussion and Poster will be published online on the ESMO website at 00:05 CEST on Thursday, 31 August 2017.
  • Late-breaking abstracts will be made public at 00:05 CEST (local Swiss time) on the day of the official Congress session during which they are presented.
  • Abstracts selected for the ESMO Press Programme* will be made public accordingly to the following schedule:

*ESMO Press Programme is still subject to changes

The following studies will be included in the official ESMO 2017 press releases.

Abstract ID Title Embargo
1273O_PR Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC) Thursday 31st Aug., at 00:05 CEST
1410P_PR The role of tumour marker testing in earlier diagnosis of cancer Saturday 2nd Sept., at 00:05 CEST
150O_PR Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy Sunday 3rd Sept., at 00:05 CEST
929O_PR ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment: Results of Primary Progression- Free Survival (PFS) analysis Monday 4th Sept., at 00:05 CEST
615O_PR Hybrid Minimally Invasive vs. Open Esophagectomy for patients with Esophageal Cancer: Long-term outcomes of a multicenter, open-label, randomized phase III controlled trial, the MIRO trial Tuesday 5th Sept., at 00:05 CEST
1412P_PR Ischemic stroke as cancer predecessor and associated predictors Wednesday 6th Sept., at 12:00 CEST (midday)
1298O_PR Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study Wednesday 6th Sept., at 00:05 CEST
1299O_PR Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC) Wednesday 6th Sept., at 00:05 CEST
LBA10_PR Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) Friday 8th Sept., at 00:05 CEST
LBA28_PR KEYNOTE-059 Update: Efficacy and Safety of Pembrolizumab Alone or in Combination With Chemotherapy in Patients With Advanced Gastric or Gastroesophageal (G/GEJ) cancer Friday 8th Sept., at 00:05 CEST
LBA40_PR ARIEL3: A Phase 3, Randomised, Double-Blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma (OC) Friday 8th Sept., at 00:05 CEST
LBA31_PR Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476) Friday 8th Sept., at 00:05 CEST
1110PD_PR Factors associated with reduced work ability in a nation-wide cohort of long-term cancer survivors treated in young adulthood (19-39 years) - the NOR-CAYACS study Saturday 9th Sept., at 00:05 CEST
1438O_PR Report on ESMO/SIOPE European Landscape project key results: Mapping the status and needs in AYA cancer care. Saturday 9th Sept.,at 00:05 CEST
1112PD_PR Real-World Productivity, Healthcare Resource Utilization (HRU), and Quality of Life (QOL) in Patients with Advanced Gastric Cancer (GC) in Canada and Europe Saturday 9th Sept.,at 00:05 CEST
1541O_PR Reproductive potential and performance of fertility-preserving procedures in BRCA mutation-positive (BRCA+) breast cancer (BC) patients (pts) Saturday 9th Sept.,at 00:05 CEST
1439O_PR Paediatric radiation therapy across Europe - a European questionnaire survey supported by the SIOPe, ESTRO, PROS and several national paediatric hematology-oncology societies (NAPHOS) Saturday 9th Sept.,at 00:05 CEST
1472P_PR Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients Saturday 9th Sept.,at 00:05 CEST
LBA1_PR PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab after chemoradiation therapy (CRT) in patients with Stage III, locally advanced, unresectable NSCLC Saturday 9th Sept.,at 00:05 CEST
1435O_PR Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in Clinical Trials Supporting US Food and Drug Administration (FDA) Approval of Orphan vs. Non-orphan Drugs. Sunday 10th Sept., at 00:05 CEST
1436O_PR How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS Sunday 10th Sept., at 00:05 CEST
1437O_PR Clinical Benefit of Randomized Controlled Trials (RCT) Supporting US Food and Drug Administration (FDA) Conversion from Accelerated to Full Approval Sunday 10th Sept., at 00:05 CEST
1124P_PR Impact of licensing and reimbursement discrepancies on patient access to cancer treatments across Europe and Canada Sunday 10th Sept., at 00:05 CEST
1408P_PR A study of body fat composition, derived from DXA-scans, in association with cancer incidence in postmenopausal women. Sunday 10th Sept., at 00:05 CEST
1465P_PR Do Oncology Patients Understand Clinical Trials? A Nationwide Study By Cancer Trials Ireland Sunday 10th Sept., at 00:05 CEST
236O_PR MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer Sunday 10th Sept., at 00:05 CEST
928O_PR Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT) Sunday 10th Sept., at 00:05 CEST
LBA37_PR Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial Sunday 10th Sept., at 00:05 CEST
LBA4_PR RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma Sunday 10th Sept., at 00:05 CEST
LBA8_PR Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238) Monday 11th Sept., at 00:05 CEST
LBA45_PR Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial Monday 11th Sept., at 00:05 CEST
LBA6_PR COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma Monday 11th Sept., at 00:05 CEST
LBA7_PR BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence Monday 11th Sept., at 00:05 CEST
LBA21_PR Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) Monday 11th Sept., at 00:05 CEST

ESMO YouTube Channel

Visit our YouTube Channel and get access to our latest videos.

ESMO Flickr Stream

Visit our  Flickr Stream and browse through our entire photo library

ESMO Asia 2016 - Day 2


Related links